AbCellera Biologics (ABCL) Stock Statistics & Valuation Metrics

AbCellera Biologics has a market cap or net worth of $1.17B. The enterprise value is ―.

AbCellera Biologics has 299,335,050 shares outstanding. The number of shares has decreased by -2.65% in one year.

AbCellera Biologics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -19.85%.

The current PE Ratio of AbCellera Biologics is ―. AbCellera Biologics’s PEG ratio is -0.68.

In the last 12 months, AbCellera Biologics had revenue of 28.83M and earned -162.86M in profits. Earnings per share was -0.55.

In the last 12 months, operating cash flow was -104.55M and capital expenditures -48.56M, giving a free cash flow of -153.11M billion.

AbCellera Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

AbCellera Biologics upcoming earnings date is Feb 24, 2026, After Close (Confirmed).

AbCellera Biologics as a current ratio of 9.81, with Debt / Equity ratio of 14.22%

In the past 12 months, AbCellera Biologics has paid -37.54M in taxes.

AbCellera Biologics EV to EBITDA ratio is -3.78, with an EV/FCF ratio of -4.13.

AbCellera Biologics has $520.67M in cash and marketable securities with $137.05M in debt, giving a net cash position of $383.62M billion.

Gross margin is -104.99%, with operating margin of -1091.69%, and net profit margin of -564.83%.

The average price target for AbCellera Biologics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy